Nanotechnology Characterization Laboratory (NCL)

The NCL serves as a resource and knowledge base for all cancer researchers in academia, industry, and government to facilitate the development and clinical translation of nanotechnologies intended as cancer therapeutics and diagnostics. NCL performs:

• characterization of strategies with proven efficacy for cancer therapy, diagnosis, or vaccines
• evaluation of novel, early-stage nanomedicine platforms with potential for cancer therapy and diagnosis
• evaluation of approaches intended to alleviate side effects, toxicities and other adverse effects associated with cancer therapy
• structure-activity relationship (SAR) studies, technology advancement, and method development contributing to improvement of the cancer nanotechnology knowledge base

To align the NCL Assay Cascade with the forward trajectory of modern oncology, we are updating the acceptance criteria to prioritize the next generation of cancer therapies. This revision reflects the current shift in cancer treatment from traditional cytotoxic agents to more innovative and targeted modalities. Therefore, the NCL Assay Cascade will no longer consider applications involving nanotechnology formulation of legacy oncology drugs, which are already approved by FDA (e.g., paclitaxel, doxorubicin). The NCL’s resources need to be dedicated to supporting high-risk, high-reward concepts that have the potential to significantly improve cancer diagnosis and therapy. This strategic shift ensures that the NCL continues to be a catalyst for the most promising and impactful innovations in cancer nanomedicine.